Abstract: The present invention relates to novel compounds possessing specific hot, pungent and spicy taste when subjected to direct pungency evaluation, which may be useful as food additives and anti-oxidants, however the said compounds do not add to any nutritional value but the synthesised compounds can possess useful pharmacological properties which is expected to find application in new test models for the development of anti-inflammatory drugs, bioavailability enhancers and for the study of hepatic drug metabolising mechanism; also relates to a process for preparing the said compounds.

Abstract: The present invention relates to a pharmaceutical composition comprising a bioactive constituent trans-tetracos-15-enoic acid and a process for the isolation of tetracos-15-enoic acid from the plant Indigofera tinctoria along with a method of treatment for hepatotoxicity.

Abstract: The present invention relates to novel compounds possessing specific hot, pungent and spicy taste when subjected to direct pungency evaluation, which may be useful as food additives and anti-oxidants, however the said compounds do not add to any nutritional value but the synthesised compounds can possess useful pharmacological properties which is expected to find application in new test models for the development of anti-inflammatory drugs, bioavailability enhancers and for the study of hepatic drug metabolising mechanism; also relates to a process for preparing the said compounds.

Abstract: The present invention relates to a process of isolation of bioactive eupalitin (3-O-O-D-galactopyranoside) of formula 1 possessing anti-osteoporosis activity by extraction of powdered leaves of Boerhaavia diffusa, with better yield:

Abstract: The present invention relates to a synergistic hepatoprotective pharmaceutical composition comprising an effective amount of trans-tetracos-15-enoic acid (TCA) and Apocynin (APO), the present invention also relates to a method of treatment for hepatotoxicity in mammals and humans.

Abstract: The present invention relates to a process for isolating plant Argyrobium roseum extract that contains flavonoid glycoside, wherein the extract possesses hypoglycaemic activity. The present invention also contemplates a composition containing the extract and a method of treating various hyperglycaemic conditions including non-insulin dependent diabetes mellitus disease condition by administering the extract.

Abstract: The present invention relates to a process for the preparation of trans-alkenoic acids of general formula CH3—(CH2)n—CH?(CH2)mCO2H where n=4 to 9 m=8 to 16. More particularly, the present invention relates to a process for the preparation of trans-tetracos-15-enoic acid, which is a bioactive constituent possessing dose-related hepatoprotective activity. The present invention also relates to the use thereof for hepatoprotection.

Abstract: The present invention relates to a novel compound 8-(C-&bgr;-D-glucopyranosyl)-7,3′,4′-trihydroxyflavone, isolated from Pterocarpus marsupium useful in the treatment of diabetes. The present invention also relates to a method for the preparation of the compound and to the uses thereof.

Abstract: The present invention relates to a process for the preparation of trans-alkenoic acids of general formula CH3—(CH2)n—CH—(CH2)m CO2H where n=4 to 9 m−8 to 16. More particularly, the present invention relates to a process for he preparation of trans-tetracos-15-enoic acid, which is a bioactive constituent possessing dose-related hepatoprotective activity. The present invention also relates to the use thereof for hepatoprotection.

Abstract: The present invention relates to a process for the isolation of a novel oligospirostanoside structurally constructed as 3-0-[&agr;-L-rhamnopyranosyl-(1→2)-&agr;-L-rhamnopyranosyl-(1→4)-0-&bgr;-D-glucopyranosyl]-25(S)-5&bgr; spirostan-3&bgr;-ol isolated from Asparagus racemosus and biologically evaluated as a potent immunomodulatory agent.

Abstract: The present invention provides a synergistic composition of bioactive fraction essentially constituting iridoid glucosides, acetyl barlerin and shanzhiside methyl ester isolated from a plant source Barleria prionitis linn along with a process for the isolation of the bioactive fraction, the present invention also relates to a method of treating mammals and humans for hepatotoxicity, stress and immuno-deficiency with the synergistic bioactive composition.

Abstract: The present invention relates to a novel oligospirostanoside having the structure 3-0-[&agr;-L-rhamnopyranosyl-(1→2)-&agr;-L-rhamnopyranosyl-(1→4)-0-&bgr;-D-glucopyranosyl]-25(S)-5&bgr;-spirostan-3&bgr;-ol isolated from Asparagus racemosus and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.

Abstract: The present invention relates to a novel compound 8-(C-&bgr;-D-glucopyranosyl)-7,3′,4′-trihydroxyflavone, isolated from Pterocarpus marsupium useful in the treatment of diabetes. The present invention also relates to a method for the preparation of the compound and to the uses thereof.

Abstract: The present invention relates to a water-soluble bioactive fraction obtained from the gum resin exudate of Boswellia serrata and to a process for the preparation thereof. The present invention also relates to a process for the isolation of a water soluble bioactive fraction containing a mixture of potassium and calcium salts of polysaccharides composed of units of arabinose, galactose and D-glucuronic acid, having marked anti-inflammatory and anti-arthritic activities from the gum resin exudate of Boswellia serrata and to the use thereof in the treatment of arthritis in the form of a pharmaceutical composition containing the bioactive fraction.

Abstract: The present invention relates to a process for the isolation of a novel oligospirostanoside structurally constructed as 3-0-[&agr;-L-rhamnopyranosyl-(1→2)-&agr;-L-rhamnopyranosyl-(1→4)-0-&bgr;-D-glucopyranosyl]-25(S)-spirostan-3&bgr;-ol isolated from Asparagus racemosus and biologically evaluated as a potent immunomodulatory agent.

Abstract: The present invention provides a synergistic composition of bioactive fraction essentially constituting iridoid glucosides, acetyl barlerin and shanzhiside methyl ester isolated from a plant source Barleria prionitis linn along with a process for the isolation of the bioactive fraction, the present invention also relates to a method of treating mammals and humans for hepatotoxicity, stress and immuno-deficiency with the synergistic bioactive composition.

Abstract: The present invention relates to a novel oligospirostanoside having the structure 3-0-[&agr;-L-rhamnopyranosyl-(1→2)-&agr;-L-rhamnopyranosyl-(1→4)-0-&bgr;-D-glucopyranosyl]-25(S)-spirostan-3&bgr;-ol isolated from Asparagus racemosus and to a pharmaceutical composition containing the novel oligospirostanoside and to a method for immunomodulation using said oligospirostanoside by administering a pharmaceutically effective amount of said novel oligospirostanoside.

Abstract: The present invention relates to a pharmaceutical composition comprising a bioactive constituent trans-tetracos-15-enoic acid and a process for the isolation of tetracos-15-enoic acid from the plant Indigofera tinctoria along with a method of treatment for hepatotoxicity.

Abstract: The present invention relates to a process of isolation of bioactive eupalitin (3-O-&bgr;-D-galactopyranoside) of formula 1 possessing anti-osteoporosis activity by extraction of powdered leaves of Boerhavia diffusa, with better yield 1

Abstract: A novel glucopyranoside, 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H) benzofuran-7-C-&bgr;-D-glucopyranoside of the formula 1 isolated from Pterocarpus marsupium and to a process for the isolation thereof is disclosed. The invention also relates to a pharmaceutical composition containing 2,6-dihydroxy-2-(P-hydroxybenzyl)-3(2H)benzofuran-7-C-&bgr;-D-glucopyranoside and to method for the treatment of diabetes using said compound.